Company: Precision Optics Corporation
Ticker: Nasdaq: POCI
Sector: Technology
Investor Contact: Robert Blum

Precision Optics Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Conference Call Scheduled for today, September 28, 2023, at 5:00pm ET

GARDNER, Mass., Sept. 28, 2023 — Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its fourth quarter and fiscal year ended June 30, 2023.

FY 2023 Financial Highlights (Year Ended June 30, 2023):

  • Revenue increased 34% to $21.0 million, a new record, compared to $15.7 million in the previous fiscal year.
  • Production revenue reached a new annual record of $14.3 million, an increase of 39% compared to the previous fiscal year.
  • Engineering revenue was a record $6.7 million, an increase of 25% compared to the previous fiscal year.
  • Gross margin was 36.8% compared to 31.4% in the previous fiscal year.
  • Net loss was ($144,613) which compared to net loss of ($928,416) in the previous year.
  • Adjusted EBITDA, defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation and other income, was a record $491,219, compared to $(242,293) in the previous fiscal year. Adjusted EBITDA for fiscal 2023 included the impact of a one-time increase in the allowance for doubtful accounts of $464,000 for a single customer.

Q4 2023 Financial Highlights (3 Months Ended June 30, 2023):

  • Revenue increased 5% to $5.02 million, compared to $4.79 million in the same quarter of the previous fiscal year.
  • Production revenue was $3.0 million compared to $3.1 million in the same quarter of the previous fiscal year.
  • Engineering revenue was $2.0 million compared to $1.7 million in the same quarter of the previous fiscal year.
  • Gross margin was 38.5% compared to 30.1% in the same quarter of the previous year.
  • Net loss for the quarter was ($96,125) which compared to net income of $269,293 in the same quarter of the previous year. Net loss for the fourth quarter of fiscal 2023 was negatively impacted by the increase in the allowance for doubtful accounts discussed above.
  • Adjusted EBITDA was $(412,026) for the quarter compared to $237,153 in the same quarter of the previous year. Adjusting for the one-time increase in the allowance for doubtful accounts, adjusted EBITDA would have been $ 51,974.

Recent Additional Highlights:

  • In April 2023, the Company announced the receipt of an initial product development order for a next-generation urological endoscopy program totaling approximately $1.3 million from an established medical device company.
  • The Company has made a significant investment in its management team. In April 2023, appointed Mahesh Lawande in the newly created role of Chief Operating Officer of Precision Optics and in June appointed Wayne Coll as Chief Financial Officer
  • In May 2023, the Company announced the receipt of a follow-on product development order for a next generation single-use urology program totaling approximately $1.5 million from an established medical device company leveraging the Company’s unique expertise in micro-optics, medical systems, and digital imaging.
  • In June 2023, the Company strengthened its balance sheet through a combination of three actions: A new $750,000 term loan with Main Street Bank; expansion of its line of credit facility to $1.25 million from $500,000; and the completion of a warrant-less common stock private placement providing $2.52 million in gross proceeds.

Precision Optics’ CEO, Joseph Forkey, commented, “Fiscal year 2023 was a year of tremendous progress for Precision Optics as we continued to leverage our unique technological and production capabilities to drive record revenues and positive Adjusted EBITDA. Our business model, where we apply our technical knowledge to support a customer from the early design phase all the way through mass manufacture, continues to show great signs of success. During fiscal year 2023, we achieved both record production revenue of $14.3 million and record engineering revenue of $6.7 million. Also, gross margins increased to 37% compared to 31% last fiscal year. We continue to increase our technical resources and to successfully attract new programs to our product development pipeline. This pipeline is the strongest indicator of long-term revenue growth potential and expanded substantially in the fourth quarter as we scaled up efforts on several key programs that we expect to be long-term contributors to our business growth.”

“I am also very excited that the Company was able to attract Mahesh Lawande, Chief Operating Officer and Wayne Coll, Chief Financial Officer, both of whom have repeated experience in driving medical device technology companies to greater levels of efficiency, profitability and growth.”

“Overall, I am pleased with the many accomplishments of fiscal year 2023. The company achieved record revenues, improved gross margins, and record Adjusted EBITDA. We have been delivering against significant customer programs and expect the pipeline of new projects to result in accelerated growth in the second half of Fiscal 2024.”

The following table summarizes the fourth quarter and fiscal year (unaudited) results for the periods ended June 30, 2023, and 2022:

Note: The Common Shares in this table reflect shares on a post reverse split basis for all periods presented.

Three Months

Fiscal Year

Ended June 30,

Ended June 30,

2023

2022

2023

2022

Revenues

$5,024,140

$4,793,511

$21,044,467

$15,678,248

Gross Profit

1,934,945

1,441,363

7,734,136

4,928,187

Stock Compensation Expenses

142,242

150,377

884,606

800,473

Business Acquisition Expenses

162,125

Other

2,398,177

1,711,456

7,488,618

5,479,479

Total Operating Expenses

2,547,419

1,861,833

8,372,684

6,442,077

Operating Income (Loss)

(612,475)

(420,470)

(638,548)

(1,513,891)

Net Income (Loss)

(96,125)

269,293

(144,613)

(928,416)

Income (Loss) per Share

Basic and Fully Diluted

$(0.02)

0.05

$(0.03)

$(0.18)

Weighted Average Common Shares Outstanding

Basic and Fully Diluted

5,687,526

5,295,720

5,666,034

5,295,720

Conference Call Details
Date and Time: Thursday, September 28, 2023, at 5:00pm ET

Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or
(412) 317-5705.

Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/nKYp4AE46Pz.

Replay: A teleconference replay of the call will be available until October 5, 2023, at (877) 344-7529 or (412) 317-0088, replay access code 5811443. A webcast replay will be available at https://app.webinar.net/nKYp4AE46Pz.

About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division’s electronic imaging expertise and its Ross Optical division’s high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

Non-GAAP Financial Measures

Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America (“non-GAAP”). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation, restructuring and other acquisition-related items.

This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.

About Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by the Company’s management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.

Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800

Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com

Following are the Company’s Consolidated Balance Sheets at June 30, 2023 and June 30, 2022, and Statements of Operations, for the three and twelve months ended June 30, 2023 and 2022:

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Consolidated Balance Sheets at June 30, 2023 and 2022

2023

2022

ASSETS

Current Assets:

Cash and cash equivalents

$

2,925,852

$

605,749

Accounts receivable, net of allowance for doubtful accounts of $606,715

at June 30, 2023 and $44,135 at June 30, 2022

3,907,407

2,663,872

Inventories

2,776,216

3,022,147

Prepaid expenses

249,681

213,448

Total current assets

9,859,156

6,505,216

Fixed Assets:

Machinery and equipment

3,227,481

3,215,412

Leasehold improvements

825,752

843,903

Furniture and fixtures

242,865

219,999

Total fixed assets

4,296,098

4,279,314

Less-Accumulated depreciation and amortization

3,862,578

3,651,843

Net fixed assets

433,520

627,471

Operating lease right-to-use asset

358,437

517,725

Patents, net

265,111

229,398

Goodwill

8,824,210

8,824,210

TOTAL ASSETS

$

19,740,434

$

16,704,020

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:

Current portion of capital lease obligation

$

43,209

$

40,705

Current maturities of long-term debt

513,259

367,714

Current portion of acquisition earn out liability

166,667

Accounts payable

2,432,264

2,239,175

Customer advances

1,174,690

905,113

Accrued compensation and other

927,521

716,702

Operating lease liability

168,677

150,565

Total current liabilities

5,259,620

4,586,641

Capital lease obligation, net of current portion

68,482

111,691

Long-term debt, net of current maturities

2,175,980

1,961,141

Acquisition earn out liability, net of current portion

705,892

Operating lease liability, net of current portion

189,760

367,160

Stockholders’ Equity:

Common stock, $0.01 par value: 50,000,000 shares authorized; issued and

outstanding – 6,066,518 shares at June 30, 2023 and 5,638,302 shares at June 30, 2022

60,665

56,383

Additional paid-in capital

60,224,934

57,009,506

Accumulated deficit

(48,239,007)

(48,094,394)

Total stockholders’ equity

12,046,592

8,971,495

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

19,740,434

$

16,704,020

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

for the Years Ended June 30, 2023 and 2022

2023

2022

Revenues

$

21,044,467

$

15,678,248

Cost of goods sold

13,310,331

10,750,061

Gross profit

7,734,136

4,928,187

Research and development expenses, net

992,375

666,479

Selling, general and administrative expenses

7,380,309

5,613,473

Business acquisition expenses

162,125

Total operating expenses

8,372,684

6,442,077

Operating loss

(638,548)

(1,513,890)

Other income (expense)

Interest expense

(218,927)

(155,658)

Gain on forgiveness of bank note

Gain on revaluation of contingent earn-out liability

714,798

742,084

Loss before provision for income taxes

(142,677)

(927,464)

Provision for income taxes

1,936

952

Net loss

$

(144,613)

$

(928,416)

Loss per share:

Basic and fully diluted

$

(0.03)

$

(0.18)

Weighted average common shares outstanding:

Basic and fully diluted

5,666,034

5,295,720

Note: The Common Shares in this table reflect shares on a post reverse split basis for all periods presented.

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

RECONCILIATION OF GAAP TO NON-GAP FINANCIAL MEASURES

ADJUSTED EBITDA

Three Months
Ended June 30,

Fiscal Year
Ended June 30,

2023

2022

2023

2022

Net loss (GAAP)

$

(96,125)

$

(113,899)

$

(144,613)

$

(928,418)

Stock based compensation

149,242

231,115

919,032

915,494

Depreciation and amortization

53,275

66,207

210,735

190,068

Interest expense

51,484

52,778

218,927

159,538

State Income Taxes

1,936

952

1,936

952

Acquisition Expense

162,125

Revaluation of earn-out liability

(571,838)

(714,798)

(742,052)

Adjusted EBITDA (non-GAAP)

$

(412,026)

$

237,153

$

491,219

$

(242,293)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/precision-optics-reports-fourth-quarter-and-fiscal-year-2023-financial-results-301942298.html

SOURCE Precision Optics Corporation

Skip to content